Last updated: July 11, 2026
Shionogi v. Amneal (1:18-cv-01564): Litigation Summary, Patent Claims, and Generic Entry Impact
Shionogi Inc. v. Amneal Pharmaceuticals, LLC (D. Del., No. 1:18-cv-01564) is a Hatch-Waxman patent infringement case tied to Shionogi’s product and Amneal’s generic application. The docket reflects a litigation posture focused on infringement/validity of listed patents rather than on any product-specific regulatory proceeding in the court record. The practical outcome for market entry risk depends on which patents were asserted, which were found not infringed or invalid (if rulings issued), and whether any settlement or consent judgment narrowed the asserted claims.
What is Shionogi v. Amneal (1:18-cv-01564) and what patents were asserted?
Core case identification
- Case: Shionogi Inc. v. Amneal Pharmaceuticals, LLC
- Court: U.S. District Court for the District of Delaware (D. Del.)
- Docket: 1:18-cv-01564
- Filing year: 2018
What this case type typically covers in Delaware
Hatch-Waxman actions in Delaware generally proceed on:
- infringement of one or more Orange Book–listed patents for a Shionogi NDA;
- invalidity defenses (non-infringement, anticipation, obviousness, indefiniteness, lack of written description/enablement);
- procedural handling of dispositive motions (claim construction, summary judgment).
Limits of this summary
A litigation summary must identify asserted patents and the case outcomes (claim construction, Markman rulings, summary judgment, trial verdict, or settlement entry terms). Those details are not present in the provided input, and generating them would risk inaccuracy.
When did Shionogi sue Amneal (timeline of key docket events)?
A complete litigation timeline requires docket-event dates such as:
- complaint filing date;
- service and answer dates;
- amended pleadings;
- Markman/claim construction scheduling;
- summary judgment motions and rulings;
- trial dates (if any);
- settlement/consent judgment filing.
No event dates were provided. Without those, a precise timeline cannot be produced.
How do Paragraph IV challenges connect to this case’s infringement theory?
For an ANDA filer like Amneal, the typical linkage is:
- Amneal submits an ANDA referencing Shionogi’s NDA;
- Amneal certifies to one or more Orange Book patents via Paragraph IV (or other certifications);
- Shionogi sues under 35 U.S.C. § 271(e)(2) within the statutory window.
Case impact pathway
- If Shionogi’s asserted patents remain enforceable, Amneal’s FDA approval/launch can be blocked until expiration or until a court ruling permits launch.
- If patents are found invalid or not infringed, Amneal can potentially launch at-risk subject to FDA marketing permission timing.
Which Delaware orders matter for generic launch risk (claim construction, summary judgment, injunction)?
For launch-risk analysis, the key artifacts are:
- Claim construction (Markman)
Drives infringement and invalidity under the correct claim scope.
- Summary judgment on infringement/invalidity
Often resolves the case or narrows to remaining issues.
- Permanent injunction or consent judgment
Sets hard launch dates tied to patent status.
- Section 271(e)(4) discussions (if any)
May address declaratory judgment or remedies.
No court order list or holdings was provided, so the specific impact cannot be mapped to enforceability or launch timing.
What settlement terms (if any) define the commercial outcome?
Many Delaware Hatch-Waxman cases end through:
- settlement with stipulated dismissal;
- consent judgments with a defined “carve-out” or agreed launch date;
- covenant-not-to-sue arrangements tied to patent expiration or design changes.
Settlement terms are critical for:
- determining the earliest likely generic entry date;
- assessing whether “design-around” formulations avoid infringement;
- calculating pay-for-delay economic scope (when settlement is publicly described).
No settlement text or docket entry identifiers were provided.
What is the Orange Book status of Shionogi’s product and how does it map to this litigation?
Orange Book mapping is normally done by:
- identifying the Shionogi NDA and reference product;
- listing patents tied to that NDA;
- aligning asserted patents in 1:18-cv-01564 with the Orange Book entries and listed expiration dates.
No NDA/product identifier was provided in the prompt, and no Orange Book listing table was included. A correct Orange Book status section requires those inputs.
Does this litigation involve formulation patents, method-of-use patents, or manufacturing process patents?
Patent estate composition affects generic entry risk:
- Formulation patents: limit launch of generics with different excipient systems, polymorphs, or release profiles.
- Method-of-use patents: limit launch only if ANDA labels use the protected method.
- Manufacturing/process patents: can constrain at-scale replication even when the drug substance is similar.
No asserted patent categories were provided. Without the patent list, the estate structure cannot be classified.
How strong is Shionogi’s patent estate versus Amneal’s potential design-arounds?
A strength analysis depends on:
- claim breadth from construction outcomes;
- prior art record cited in invalidity theories;
- whether courts treat specific claim elements as limiting;
- whether any asserted claims are narrow and easy to design around.
No holdings, claim construction results, or asserted claim language were supplied, so strength cannot be quantified.
How does Shionogi v. Amneal compare with other Shionogi generic challenges in Delaware?
Comparative analysis typically uses:
- whether Shionogi relies on the same patent families across multiple ANDA defendants;
- whether courts consistently sustain validity/infringement for those families;
- whether settlements produce similar launch schedules.
No adjacent case list or patent families were provided.
What generic entry risks exist for Amneal if Shionogi wins or if Shionogi loses?
If Shionogi wins (infringement sustained and/or invalidity rejected):
- Amneal typically cannot market until patent expiration or further appellate outcomes.
- FDA approval timing may still occur, but launch is blocked.
If Shionogi loses (invalidity or non-infringement):
- Amneal may launch promptly after FDA marketing authorization, subject to any remaining barriers from other patents.
- At-risk launch exposure may be relevant if appeals or stay motions arise.
The direction of outcome is not contained in the prompt.
What should investors and licensors infer from the case posture and docket outcome?
Investors and licensors treat the action as:
- a signal of asserted patent leverage;
- a proxy for the likelihood of generic entry and revenue erosion;
- an indicator of whether Shionogi prefers litigating specific patent types.
But converting posture into actionable inference requires the actual procedural outcome, which is not provided.
Key Takeaways
- Shionogi Inc. v. Amneal Pharmaceuticals, LLC (D. Del., 1:18-cv-01564) is a Hatch-Waxman–style patent infringement dispute in Delaware tied to Shionogi’s Orange Book–listed patents and Amneal’s generic ANDA strategy.
- A business-grade litigation summary requires the asserted patent list, the specific court rulings, and any settlement or consent judgment terms. Those are not contained in the provided information.
- Launch-risk and patent-estate strength cannot be accurately analyzed without docket holdings and patent identification.
FAQs
- What court orders typically determine the launch date in Delaware Hatch-Waxman cases like 1:18-cv-01564?
- How do Paragraph IV certifications influence what patents get asserted in Shionogi v. Amneal?
- What evidence matters most for infringement in generic drug patent cases (comparative exhibits, samples, labels)?
- How do settlements in Hatch-Waxman cases change FDA timing and marketing restrictions?
- What are the most common Delaware defenses to patent infringement allegations in ANDA litigation?
References
- U.S. District Court for the District of Delaware, case docket Shionogi Inc. v. Amneal Pharmaceuticals, LLC, No. 1:18-cv-01564 (2018).
